Form 4: Lynx1 Capital Management LP Increases Stake in TScan Therapeutics

Lynx1 Capital Management LP has increased its holdings in TScan Therapeutics through a recent purchase of common stock.

Summary

• Lynx1 Capital Management LP purchased 947 shares of TScan Therapeutics common stock on November 15, 2024.
• The shares were bought at a weighted average price of $4.3442, with individual transaction prices ranging from $4.335 to $4.350.
• Following this transaction, Lynx1 Capital Management LP beneficially owns 5,225,547 shares of TScan Therapeutics indirectly through Lynx1 Master Fund LP.
• Weston Nichols, as the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager, disclaims beneficial ownership except to the extent of his pecuniary interest.

Sentiment

Score: 6

Explanation: The document is a routine SEC filing detailing a stock purchase. It is neutral in sentiment, reflecting a standard transaction rather than any significant positive or negative news. The increase in ownership could be seen as a slightly positive signal.

Positives

• Lynx1 Capital Management LP has increased its investment in TScan Therapeutics, which could be seen as a positive signal for the company's prospects.

Risks

• The document does not provide any specific risks, but it is important to note that the investment decisions of Lynx1 Capital Management LP are subject to market fluctuations and the performance of TScan Therapeutics.

Management Comments

• Weston Nichols, the sole member of Lynx1 Capital Management GP LLC, disclaims beneficial ownership of the securities except to the extent of his pecuniary interest.

Industry Context

This filing reflects a change in ownership by a significant investor in TScan Therapeutics, a biotechnology company. Such filings are common in the biotech industry as institutional investors adjust their positions based on company performance and market conditions.

Comparison to Industry Standards

• SEC Form 4 filings are a standard practice for reporting changes in beneficial ownership by insiders and significant shareholders in publicly traded companies.
• The transaction is typical for institutional investors managing funds and adjusting their portfolios.
• The level of detail provided in the filing is consistent with SEC requirements for transparency.

Stakeholder Impact

• The increased ownership by Lynx1 Capital Management LP could be viewed positively by other shareholders, potentially increasing confidence in the company.

Key Dates

Keywords

TScan Therapeutics, Lynx1 Capital Management, Stock Purchase, Beneficial Ownership, SEC Form 4, Investment Management